Related articles

Cancer development is often the result of interactions between genetic and environmental factors. Understanding the genetic background of cancer is crucial for assessing individual risk, developing preventive strategies, and conducting early screenings.

Surgery is often the first step in the treatment of cancer patients. However, even when the surgery successfully removes the tumor, the risk of cancer recurrence still exists. Traditional imaging and histological tests can only detect significant changes when the tumor has grown or metastasized, making it impossible to capture the tiny remnants of cancer cells in time. This means that many patients may appear to be cancer-free after surgery, but potential cancer cells remain, leading to disease recurrence.

With advancements in tumor detection technology, liquid biopsy has emerged as a non-invasive method with immense potential in early tumor screening, metastasis monitoring, and treatment evaluation. Particularly, RGCC CTC (Circulating Tumor Cell) testing is gaining increasing importance in tumor care. This technology provides crucial information on tumor metastasis while simultaneously assessing the patient’s nutritional status, offering valuable insights for developing personalized care plans.

Cancer is a multifactorial disease influenced by genetic, environmental, and lifestyle factors. With advancements in molecular biology and genetic technologies, personalized medicine is becoming a cornerstone of early cancer detection and management. Onco-D-clare, an advanced cancer risk assessment tool, integrates genetic data analysis and molecular diagnostics to provide a comprehensive understanding of individual cancer risks. This article explores the principles, applications, and potential impact of Onco-D-clare on cancer risk management.

The continuous advancement of cancer detection technology has provided more options for the formulation of precision care and personalized plans. Among them, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA), as two core liquid biopsy technologies, have attracted much attention due to their unique advantages. However, in practical applications, how to choose appropriate detection methods based on the patient’s specific situation and care goals has become a key issue. This article will explore in depth the characteristics, applicable scenarios, and application potential of CTC and ctDNA in cancer care.

Oncotrace is a blood-based diagnostic technology developed by RGCC (The Research Genetic Cancer Center), designed to detect circulating tumor cells (CTCs) and related biomarkers in cancer patients’ blood. This test aims to provide real-time monitoring and assessment of cancer progression, predict the risk of recurrence, and guide personalized treatment strategies, ultimately improving patient outcomes and quality of life.